Allena Pharmaceuticals Inc., of Newton, Mass., said the European Commission has granted orphan drug designation to Allena's investigational product, ALLN-177, Bacillus subtilis oxalate decarboxylase, for the treatment of primary hyperoxaluria (PH), a condition characterized by markedly elevated urinary oxalate excretion.